Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

BACKGROUND: The optimal timing of (neo)adjuvant trastuzumab initiation with respect to chemotherapy and surgery remains undefined. METHODS: Retrospective analysis of a large institutional database of HER2-positive patients who received anti-HER2 therapy. We included all Stage I to III patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gullo, Giuseppe, Walsh, Naomi, Fennelly, David, Bose, Reetesh, Walshe, Janice, Tryfonopoulos, Dimitrios, O’Mahony, Kate, Hammond, Lisa, Silva, Nuno, McDonnell, Deirdre, Ballot, Josephine, Quinn, Cecily, McDermott, Enda W., Evoy, Denis, Prichard, Ruth, Geraghty, James, Amstrong, John, Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070916/
https://www.ncbi.nlm.nih.gov/pubmed/29773838
http://dx.doi.org/10.1038/s41416-018-0114-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070916/
https://www.ncbi.nlm.nih.gov/pubmed/29773838
http://dx.doi.org/10.1038/s41416-018-0114-x

Ejemplares similares